Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 721 in Gilead Sciences

  1. While Gilead's Profits Soar, Uncertainty Reigns Supreme At AbbVieRead the original story w/Photo

    12 hrs ago | Seeking Alpha

    This article analyzes AbbVie using the DRAG framework and compares the company's fundamental attributes with those of Gilead Sciences. While AbbVie's dividend yield and dividend growth profile are impressive, its balance sheet is highly levered and analysts offer only modest earnings growth projections.

    Comment?

  2. AbbVie to Sell Hepatitis C Drug at 12% Discount to Gilead RivalRead the original story

    14 hrs ago | The Washington Post

    AbbVie Inc. and Enanta Pharmaceuticals Inc.'s hepatitis C combination drug will be about 12 percent cheaper than its rival from Gilead Sciences Inc., setting the stage for fierce competition for patients of the liver virus. The cocktail of pills, which will be sold under the name Viekira Pak, will cost $83,319 for a 12-week course of treatment, AbbVie said today.

    Comment?

  3. AbbVie says newly approved hepatitis C treatment costs $83,319Read the original story

    15 hrs ago | Reuters

    An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc. U.S. health regulators earlier on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead.

    Comment?

  4. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    15 hrs ago | Business Wire

    ... de las enfermedades malignas de clulas B y otras enfermedades )--ONO PHARMACEUTICAL CO., LTD. ("ONO") y Gilead Sciences, Inc. (Nasdaq:GILD) han anunciado que las empresas han firmado un acuerdo exclusivo d... )--Fitch Ratings has been notified of a ...

    Comment?

  5. Ono Pharmaceutical Company, Ltd. And Gilead Sciences, Inc. Announce...Read the original story

    Yesterday | BioSpace

    OSAKA, Japan & FOSTER CITY, Calif.-- --ONO PHARMACEUTICAL CO., LTD. and Gilead Sciences, Inc. today announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO's oral Bruton's tyrosine kinase inhibitor for the treatment of B-cell malignancies and other diseases.

    Comment?

  6. ONO and Gilead Announce Exclusive License Agreement to Develop BTK...Read the original story

    Yesterday | Customer Interaction Solutions

    ONO PHARMACEUTICAL CO., LTD. and Gilead Sciences, Inc. today announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO's oral Bruton's tyrosine kinase inhibitor for the treatment of B-cell malignancies and other diseases.

    Comment?

  7. Sky-high price has VA rationing hep C drugRead the original story w/Photo

    Thursday | The Daily Republic

    Sen. Bernie Sanders, I-Vermont, used one of his last hearings as chairman of the Senate Veterans Affairs Committee to review how VA has had to ration a break-through medicine that cures hepatitis C, a liver virus infecting 174,000 veterans, because a course of treatment - 84 pills over 12 weeks - costs VA almost $50,000 per patient. Sanders said the biopharmaceutical company Gilead Sciences, Inc., of Foster City, stands to earn more than $200 billion on a new drug called Sovaldi.

    Comment?

  8. Biogen Idec Poised To Continue Its Stellar RunRead the original story w/Photo

    Thursday | Seeking Alpha

    Biogen Idec is a rare example of a large cap stock trading at less than 20 times forward earnings with an anticipated earnings growth rate of more than 20%. While the company generates a lower return on invested capital and trades at a higher multiple than Gilead Sciences, its balance sheet is significantly more conservative than Gilead's.

    Comment?

  9. Biotech: More Upside in 2015?Read the original story w/Photo

    Thursday | Barron's

    Bernstein's Geoffrey Porges and Wen Shi are bullish on biotech companies like Gilead Sciences , Celgene and Medivation heading into 2015. The reason: The first biotech conference of the year.

    Comment?

  10. Biotech Predictions for Large Cap Firms Include Medivation, Inc., Gilead Sciences, Inc.Read the original story

    Wednesday | BioSpace

    ... ty. In this context, we see selective opportunities in our coverage, including Medivation, Inc. ( MDVN ) and Gilead Sciences, Inc. ( GILD ) in the short term.

    Comment?

  11. Panel finds Gilead's $95K hepatitis C drug is worth it - but unaffordableRead the original story w/Photo

    Wednesday Dec 17 | Business Journal

    Gilead's Harvoni - the first once-daily tablet targeting chronic hepatitis C - is worth its eye-popping $95,000 price, the California Technology Assessment Forum has said. But the state simply can't afford it.

    Comment?

  12. 5 key events in Bay Area biotech in 2014Read the original story w/Photo

    Friday Dec 5 | Business Journal

    The $1,000 pill Payers and patients attacked Gilead Sciences Inc. and CEO John Martin over the $1,000-a-pill cost of the Foster City-based company's groundbreaking hepatitis C drug Sovaldi. The company even received inquiries from a handful of legislators in Congress who asked just how Gilead came up with the price of Sovaldi.

    Comment?

  13. How To Beat The Market - My Best Large-Cap Stock Portfolio: Gilead SciencesRead the original story w/Photo

    Tuesday Dec 16 | Seeking Alpha

    ... formulas has turned out to be very successful, and in this article, I will describe that strategy. Since Gilead Sciences Inc. (NASDAQ: GILD ) is the first ranked stock by that strategy, I will also focus on that company. The strategy is based on ...

    Comment?

  14. Which Biotech Will Become the Next Gilead Sciences, Inc.?Read the original story w/Photo

    Tuesday Dec 16 | The Motley Fool

    When it comes to investing in the biotech sector, perhaps no company has been a better poster child for success than Gilead Sciences . Over the trailing three years Gilead shares have rocketed higher by better than 400% as existing therapies and newly introduced drugs have sent sales through the roof.

    Comment?

  15. There Is Still Time To Join The Gilead BandwagonRead the original story w/Photo

    Monday Dec 15 | Seeking Alpha

    If you invest primarily in the healthcare sector like I do, chances are you have Gilead Sciences Inc. in your portfolio. Since the start of 2012, Gilead has returned its investors more than 400%.

    Comment?

  16. "Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014" is now available at Fast Market ResearchRead the original story

    Monday Dec 15 | PR-inside.com

    ... projects and understanding the factors that drove them from pipeline Companies Mentioned in this Report: Gilead Sciences, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Genmab A/S, Celgene Corporation, Onyx Pharmaceuticals, Inc., Bayer AG, ...

    Comment?

  17. Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology TherapeuticsRead the original story

    Monday Dec 15 | Freshnews

    Gilead Sciences, Inc. today announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, Executive Vice President, Clinical Research and will have responsibility for Gilead's programs in oncology.

    Comment?

  18. Gilead raids Genentech to add to cancer ranksRead the original story w/Photo

    Monday Dec 15 | Business Journal

    Gilead Sciences Inc. , coming off its first cancer drug approval and with more in its portfolio, hired Dr. Philippe Bishop away from Genentech Inc. to head its cancer drug programs. Bishop since 2007 had been vice president of oncology product development at South San Francisco-based Genentech, running dozens of drugs through hundreds of clinical trials.

    Comment?

  19. Philippe C. Bishop, MD , To Join Gilead Sciences, Inc. As Senior...Read the original story

    Sunday Dec 14 | BioSpace

    Gilead Sciences, Inc. today announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, Executive Vice President, Clinical Research and will have responsibility for Gilead's programs in oncology.

    Comment?

  20. Weekly Insider Sells Highlight: WAT, KO, GILD, AZO, MASRead the original story

    Sunday Dec 14 | GuruFocus.com

    According to GuruFocus Insider Data , the largest insider sells during the past week were: Waters Corp, Coca-Cola Co, Gilead Sciences Inc, Autozone Inc, and Masco Corp. EVP and President, Waters Div of Waters Corp Arthur G Caputo sold 199,500 shares during the past week at an average price of $111.56. Arthur G Caputo owns at least 88,679 shares after this.

    Comment?